Business Context and Reporting Period
This Form 8-K Current Report was filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on October 20, 2011, covering events that occurred on October 14, 2011. The filing details significant changes to the composition and leadership structure of the Company's Board of Directors.
Key Financial Metrics
This filing does not contain current period financial statements, revenue, profit, cash flow, or liquidity metrics. The only financial data referenced is historical: the Company received initial proceeds of $3,674,998 from a private placement transaction consummated on May 20, 2010.
Material Changes
- Board Expansion: The Board size was increased from seven to ten directors.
- New Director Appointments: Michael Brauser, Barry Honig, and William Spengler were elected as directors effective immediately.
- Leadership Restructuring: Messrs. Brauser and Honig were appointed as Co-Chairmen of the Board. Frank L. Jaksch Jr., the Chief Executive Officer, continues as a director but is no longer the sole Chairman.
- Compensation: Messrs. Brauser and Honig will receive standard non-cash compensation for non-employee directors. Mr. Spengler will receive no additional compensation for his board service beyond his existing salary as President.
Management Commentary and Risks
The filing highlights the professional backgrounds of the new directors, emphasizing expertise in corporate finance, capital restructuring, and the pharmaceutical/biotechnology sectors. Mr. Spengler, who has served as President since November 2010, brings experience from Smith & Wesson Holding Corp. and MGI PHARMA, Inc. The Board has not yet determined committee assignments for the new directors. Standard indemnification agreements were executed for all new directors.
Investor Verification Checklist
- Verify the specific non-cash compensation amounts for non-employee directors as disclosed in the 2010 Annual Report (Form 10-K).
- Confirm the current status of the Board committees and whether the new directors have been assigned to specific committees.
- Review the Company's most recent financial filings (10-K or 10-Q) for current liquidity and operational metrics, as this 8-K contains none.
- Check for any subsequent filings regarding the strategic rationale for the board expansion and the appointment of Co-Chairmen.